

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer

V. Conteduca^{1*}, E. Scarpi², P. Caroli³, S. Salvi⁴, C. Lolli¹, S. L. Burgio¹, C. Menna¹, G. Schepisi¹, S. Testoni², G. Gurioli⁴, G. Paganelli³, V. Casadio⁴, F. Matteucci³, U. De Giorgi¹

¹Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Maroncelli 40, 47014 Meldola, Italy

²Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

³Nuclear Medicine Operative Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

⁴Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Supplementary Table S1. PSA Response Rate according to AR copy number and TLA/MTV

	PSA Response Rate		p
	No	Yes	
	No. (%)	No. (%)	
AR N & TLA <563979	10 (43.5)	6 (40.0)	0.282
AR N & TLA ≥563979	6 (26.1)	2 (13.3)	
AR A & TLA <563979	1 (4.3)	4 (26.7)	
AR A & TLA ≥563979	6 (26.1)	3 (20.0)	
AR N & MTV <112	9 (39.1)	6 (31.6)	0.528
AR N & MTV ≥112	7 (30.4)	6 (31.6)	
AR A & MTV <112	1 (4.4)	3 (15.8)	
AR A & MTV ≥112	6 (26.1)	4 (21.0)	

Abbreviations: A, amplified; AR, androgen receptor; CI, confidence interval; MTV, metabolic tumor volume; N, normal; TLA, total lesion activity.